Context: Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma 23 (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high lipid-24 containing tissues. mitotane-treated patients were found independent of cholesterol transporter expression, scavenger 36 receptors (SrB1) and LDL-Receptors. In vitro studies showed significant higher anti-proliferative and 37 pro-apoptotic effects and higher cell and mitochondrial uptake of mitotane when H295R cells were 38 grown in LP-F medium. Finally, retrospective study of an ACC cohort of 26 mitotane-treated patients 39 revealed that statin therapy was significantly associated with a higher rate of tumor control. 40
Introduction

45
Mitotane is the only drug approved in advanced adrenocortical carcinoma (ACC) (1). The antitumor 46 clinical impact of mitotane has been shown on both prospective and retrospective studies that found 47 partial response rates in 10 to 33% of patients treated with mitotane alone but also improved overall 48 survival (2,3). Based on these results, mitotane is also recommended as an adjuvant therapy in ACC 49 patients at high risk of recurrence (4-6). In both indications, plasma mitotane monitoring is 50 recommended to look for a therapeutic window of 14-20 mg/L (1). Indeed, several studies have 51 reported higher response rate and/or a prolonged survival in patients with plasma mitotane levels 52 above 14 mg/L (7-11). In addition, neurological toxicities have been described with plasma level 53 above 20 mg/L (11,12). 54
Mitotane is also known as o,p'-DDD, an insecticide-derivative lipophilic drug that accumulates in 55 lipoproteins (13). Dyslipidemia have been observed in mitotane-treated patients but the mitotane-56 induced dyslipidemic profile differs from one study to another (14-19). The mechanism of mitotane-57 induced hypercholesterolemia is not fully understood but could be related to an activation of 58
HMGCoA reductase (20) and to an increase in cholesterol and lipoproteins synthesis (14). Little is 59 known about the influence of dyslipidemia on mitotane distribution among lipoproteins and about the 60 influence of this distribution on its anti-tumor efficacy. 61
Mechanism of mitotane action was poorly understood until recently. Two mitotane metabolites are 62 described: o,p'-DDE and o,p'-DDA, the latter being described as the main urinary metabolite of o,p'-63 DDD (21). We recently reported evidence that o,p'-DDA is unlikely an active metabolite of mitotane 64 (22). Several studies suggested that mitotane could have a mitochondrial effect (23,24), and more 65 specifically, our group demonstrated a mitotane-induced defect in cytochrome c oxidase (complex IV 66 of the mitochondrial respiratory chain) (25) . 67
In the present study, we explored the biologic implication of serum lipoproteins on mitotane 68 pharmacological action using human plasma samples, tissues of mitotane-treated patients and finally 69 in vitro on human adrenocortical H295R cells. Altogether, our results showed that lipoprotein-free 70 mitotane appeared to be the most efficient form. Based on these findings, we retrospectively examined 71 the disease control rate of 26 consecutive stage IV-ACC patients treated with mitotane, according to 72 the concurrent use of statins. 73
74
Patients, material and methods
75
Patients 76
Medical files of 70 metastatic ACC patients treated with mitotane, followed between 2007 and 2014 at 77
Gustave Roussy were retrospectively reviewed to study the correlation between occurrence of 78 dyslipidemia or statin therapy (Rosuvastatin not metabolized by Cyp3A4) within the first 3 months of 79 mitotane therapy and neurological toxicity or tumor response. Inclusion criteria were patients with 80
stage IV ACC treated with mitotane after 2007 and the exclusion criteria was the absence of lipid 81 profile available within the first 3 months of mitotane therapy. In each file, the following criteria were 82 recorded: mitotane plasma level, HDL, LDL triglycerides levels (high HDL, high LDL or high 83 triglycerides defined as above 1.5 time the upper value, concurrent use of statins given during at least 84 3 months of mitotane therapy, presence of neurological toxicities and disease control rate (stabilization 85 and partial response) at 6 months according to RECIST 1.1 (26). An informed consent was obtained 86 from all patients. 87
88
Human plasma samples and human adrenal tissues 89
Twenty-five plasma samples form 20 mitotante-treated ACC patients were taken at Gustave Roussy 90 hospital and thanmade available for this study form the central repository of HRA Phama (Paris, 91 France) to evaluate lipoprotein partitioning in normal and dyslipidemic samples. To analyze the 92 correlation between mitotane concentrations and cholesterol transporter expression, human adrenal 93 tissues were obtained from 6 mitotane-treated patients followed at Gustave Roussy or Bicêtre 94
Hospital. All were ACC but one who underwent bilateral adrenalectomy for an ectopic Cushing 95 syndrome. Tissues were collected while patients underwent surgery for therapeutic reasons. Tissues 96 were lysed in H 2 O using a TissueLyser apparatus (Qiagen, Courtaboeuf, France). All patients signed 97 an informed consent. 98
99
Human adrenocortical cells and mitochondria isolation 100
For in vitro studies, H295R cells (from passage 2 to 15) were cultured as previously described (25 Mundelsheim, France) were solubilized in culture medium and used at final concentrations of 9.6 108 mg/L (low) and 38.4 mg/L (high) for cholesterol and 1.8 mg/L (low) and 3.6 mg/L (high) for BSA. 109
Mitochondrial fractions were purified and prepared from permeabilized cells using digitonin and 110 percoll as previously described (27) . Individual lipoprotein subfractions were isolated from fetal calf serum by isopycnic density gradient 119 ultracentrifugation for 48 h at 288,000 g using a Beckman XL70 centrifuge and a SW41 rotor as 120 previously described (28). After centrifugation, gradients were collected from the top of the tubes with 121
an Eppendorf precision pipette in fractions corresponding to LDL subfractions (density < 1.063 g/mL) 122 and HDL sub-fractions (density from 1.063 g/mL to 1.179 g/mL). 123
124
Measurements of o,p'DDD in plasma, tissues, cells and mitochondria 125
Analyses of plasma samples were conducted by high performance liquid chromatography combined to 126 an ultraviolet detection (HPLC-UV) as previously described (22) and analyses of cells and 127 mitochondria samples were conducted by gas chromatography combined to a mass spectrometry 128 (GCMS). All samples were spiked with known amounts of p,p'-DDE used as an internal standards 129 
Western Blot analysis 154
Total protein extracts were prepared as previously described (22). Western Blot analyses were 155 performed as described (22). Antibodies used were a rabbit anti-BCL2 antibody (1:500 dilution, Cell 156
Signaling, Saint Quentin en Yvelines, France) with a mouse anti-α-Tubulin antibody (1:10,000 157 dilution, Sigma-Aldrich) or a rabbit anti-CYP11A1 antibody (1:500 dilution, Sigma-Aldrich) with a 158 mouse anti-GAPDH antibody (1:10,000 dilution, Sigma-Aldrich). Proteins were visualized with an 159
Odyssey-Fc apparatus (LI-COR). 160
Statistical Analysis 161
Results are expressed as means ± SEM of n independent replicates performed in the same experiment 162 or from separated experiments (n). Correlation was tested with a Pearson test. Non-parametric Mann 163
Whitney tests were used when appropriate and differences between groups were analyzed using non-164 parametric Kruskall-Wallis multiple comparison test followed by a post-test of Dunn's (Prism 165 software, GraphPad, CA). Difference between groups of patients was assessed using the Fisher's exact 166 test. A P value of 0.05 was considered as statistically significant (*P<0.05; **P<0.01; ***P<0.001). 167 To further explore which LP subfraction might account for mitotane uptake in human ACC tissue, we 185 measured the relative expression of genes encoding for SrB1 (Scavenger B1 receptor, HDL receptor) 186
Results
168
Distribution of o,p'-DDD and its metabolites among lipoproteins and lipoprotein-free
and LDL-R in six samples of human adrenal tissue collected from one ectopic Cushing's disease and 5 187 ACC mitotane-treated patients (Table 1) conditions. In LP-F medium, mitotane strongly inhibited COX2 expression (encoded by the 220 mitochondrial mtDNA for the subunit 2 of cytochrome c oxidase or respiratory chain complex IV, 221 Figure 3C ) but also StAR and CYP11A1 involved in steroidogenesis (Suppl. Figure S3A and B). LP-F 222 condition also led to a drastic reduction in CYP11A1 protein expression in H295R cells after a 48h 223 treatment with 50 µM mitotane (Suppl. Figure S3C) . Collectively, our findings provide additional 224 evidence that lipoprotein-free mitotane was the most efficient leading to alter cellular functions. 
BCL2 (Figure 4B). This was accompanied by an significant increase in intracellular o,p'-DDD 235
concentration when lipoproteins receptors were inhibited with BLT1 ( Figure 4C ). Free cholesterol was 236 added into the culture medium to saturate lipoproteins in an attempt to reduce lipoprotein-bound 237 mitotane through cholesterol exchange, thus potentially enhancing LP-F mitotane bioavailability. 238
Cholesterol supplementation in the medium dose-dependently enhanced mitotane cytotoxic effects, 239 confirming the key role of LP-F mitotane in vitro ( Figure 4D) . 240
241
Efficiency of unbound mitotane in vitro 242
To examine the relative contribution of free and protein-bound mitotane on H295R cell proliferation 243 or apoptosis, the impact of mitotane was compared in FCS-free medium, devoid of protein and 244 lipoproteins, supplemented with increasing concentrations of bovine-serum albumin (BSA) and in LP-245 F media. Consistently, o,p'-DDD was more efficient in inhibiting cell proliferation in protein-free 246 medium while BSA supplementation dose-dependently impaired mitotane efficiency ( Figure 4E) . 247
Moreover, relative caspase activity was 4-fold higher in mitotane treated cells when incubated in the 248 absence of protein than in the control medium ( Figure 4F ). Altogether, our results demonstrate that the 249 most potent activity in vitro was achieved with free mitotane. 250
251
Statin therapy and disease control rate in stage IV-ACC patients 252
To translate these observations into the clinic, we retrospectively collected data from ACC patients 253 We then explored the role of mitotane binding to each lipoprotein subfraction or lipoprotein-free 287 mitotane on its cytotoxic effect in human adrenocortical H295R cells. We provided evidence that 288 mitotane exerts a more efficient anti-proliferative and pro-apoptotic action when cells are grown in 289 LP-F medium suggesting that lipoprotein-bound mitotane is not the most potent pharmacological 290
vehicle. 291
In the present study, we also confirm that mitochondrion is a critical target of mitotane action since 292 most intracellular mitotane was recovered within the mitochondrial compartment, consistent with our 293 previous results (25). Herein, we further demonstrated that LP-F mitotane was more effectively 294 captured by mitochondria and more efficient in inhibiting the respiratory chain activity. Experiments 295 using BLT1, an SrB1 receptor inhibitor, or cholesterol saturation, that both favour mitotane action 296 through its LP-F fraction, comfort the prominent pharmacological role of free mitotane by showing an 297 increased efficiency of mitotane when added to the culture medium. These results do not exclude that 298
SrB1 could be involved in mitotane efflux. Van Slooten first suggested that albumin-bound mitotane 299 might be responsible for at least the neurological side effects observed in patients (12). We further 300 evaluated the impact of albumin on o,p'-DDD toxicity in H295R cells, and unambiguously 301 demonstrated that free mitotane exerts the most efficient pharmacological properties. 302
Altogether, our results indicate that free mitotane induces the most potent cytotoxic effects, 303 questioning the precise molecular mechanism of its transmembrane transport and yet excluding that 304 intracellular transport of lipoproteins might play a major role in the adrenal specificity of mitotane 305
action. 306
In ACC patients, a variable delay of several weeks between mitotane initiation and anti-tumorigenic 307 effect is well described in the literature (2). Consistent with our results demonstrating that free 308 mitotane might constitute the active form of the drug, this delay may correspond to the time required 309 to fully saturate circulating lipoproteins in patients' plasma. To further explore the implication of our 310 in vitro results in humans, and based on clinical and biochemical data collected from a cohort of ACC, 311 mitotane-treated patients, we examined mitotane plasma levels, lipid profile as well as neurological 312 toxicity and clinical responses according to RECIST at 1, 3 and 6 months after mitotane initiation. 313
Among the 26 patients included, 20 (76.9%) had dyslipidemia under mitotane therapy, including 314 isolated hypertriglyceridemia, hypercholesterolemia (HDL and/or LDL) or both, in accordance to 315 previous reports (16-19). More interestingly, we found that patients who received statins (42.3%), 316 presented with a better tumor control including stable disease and partial responses. We hypothesize 317 that statins, through a reduction of plasma lipoproteins levels could lead to an increased free mitotane 318 ratio. Despite the hypothesis of van Slooten who suggested that albumin-bound mitotane could be 319 responsible for neurological toxicity, we didn't find any association between LDL, HDL or statins and 320 neurological side effects. Our study has clear limitation including the small sample size, the 321 heterogeneity in patients' follow-up and plasma collections and the uncontrolled nature of the design 322 inherent to a the retrospective data collection. These preliminary data should be further confirmed and 323 the question on whether patients could benefit from statins is presently being addressed through an 324 ongoing prospective study (MITOLIPO Study) . 325
In sum, we provide strong evidence that o,p'-DDD unbound to lipoprotein fractions is more efficient 326 in vitro and that patients could benefit strategies that aim to increase LP-F mitotane fraction. The 327 potential role of dyslipidemia and statin therapy on mitotane effects will be further explored in a 328 prospective study. 
